Evidence map›Paper›PMID 35008816›Full record

ArticleInternational journal of molecular sciences2021

Searching for the Best Transthyretin Aggregation Protocol to Study Amyloid Fibril Disruption.

Elisabete Ferreira, Zaida L Almeida, Pedro F Cruz, Marta Silva E Sousa, Paula Veríssimo, Rui M M Brito

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Elisabete FerreiraChemistry Department and Coimbra Chemistry Centre-Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535 Coimbra, Portugal.
Zaida L AlmeidaChemistry Department and Coimbra Chemistry Centre-Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535 Coimbra, Portugal.ORCID 0000-0002-4097-2766
Pedro F CruzChemistry Department and Coimbra Chemistry Centre-Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535 Coimbra, Portugal.ORCID 0000-0003-3578-0134
Marta Silva E SousaChemistry Department and Coimbra Chemistry Centre-Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535 Coimbra, Portugal.
Paula VeríssimoCentre for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal.ORCID 0000-0003-0532-4242
Rui M M BritoChemistry Department and Coimbra Chemistry Centre-Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535 Coimbra, Portugal.ORCID 0000-0001-9128-2557
University of Coimbra · PT

Funding

Fundação para a Ciência e a Tecnologia PTDC/QUI-QUI/122900/2010Fundação para a Ciência e a Tecnologia RECI/QEQ- 551 QFI/0168/2012Fundação para a Ciência e a Tecnologia SFRH/BD/137991/2018Fundação para a Ciência e a Tecnologia UID/NEU/04539/2013Fundação para a Ciência e a Tecnologia UID/QUI/00313/2019Programa Operacional Temático Factores de Competitividade CENTRO-07-CT62-FEDER-002012
6 · The paper itself

Abstract

Several degenerative amyloid diseases, with no fully effective treatment, affect millions of people worldwide. These pathologies-amyloidoses-are known to be associated with the formation of ordered protein aggregates and highly stable and insoluble amyloid fibrils, which are deposited in multiple tissues and organs. The disruption of preformed amyloid aggregates and fibrils is one possible therapeutic strategy against amyloidosis; however, only a few compounds have been identified as possible fibril disruptors in vivo to date. To properly identify chemical compounds as potential fibril disruptors, a reliable, fast, and economic screening protocol must be developed. For this purpose, three amyloid fibril formation protocols using transthyretin (TTR), a plasma protein involved in several amyloidoses, were studied using thioflavin-T fluorescence assays, circular dichroism (CD), turbidity, dynamic light scattering (DLS), and transmission electron microscopy (TEM), in order to characterize and select the most appropriate fibril formation protocol. Saturation transfer difference nuclear magnetic resonance spectroscopy (STD NMR) was successfully used to study the interaction of doxycycline, a known amyloid fibril disruptor, with preformed wild-type TTR (TTRwt) aggregates and fibrils. DLS and TEM were also used to characterize the effect of doxycycline on TTRwt amyloid species disaggregation. A comparison of the TTR amyloid morphology formed in different experimental conditions is also presented.

Indexed as

Protein AggregatesAmyloidCircular DichroismDoxycyclineHydrogen-Ion ConcentrationNephelometry and TurbidimetryPrealbuminProtein Structure, SecondaryProton Magnetic Resonance SpectroscopyAmyloidDoxycyclinePrealbuminProtein Aggregatesamyloid disruptorsamyloid fibrilsamyloidosisfibril disaggregationprotein aggregationscreening protocoltransthyretin

Identifiers

PMID35008816
PMCPMC8745744
OpenAlexW4206421995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.